Nurix Therapeutics Inc at JPMorgan Healthcare Conference Transcript
All right. Good afternoon. I'm Eric Joseph, senior biotech analyst with JPMorgan. Our next presenting company is Nurix Therapeutics, and presenting on behalf of the company is CEO, Arthur Sands. There is a Q&A session after the presentation. If you got a question, we'll bring a mic to you. For those tuning in via the webcast, you can also submit questions via the portal. So with that, Arthur, thanks for joining us.
Thank you, Eric. And I'd like to thank the entire JPMorgan team for inviting us, and for another great JPMorgan conference this year. I will be making certain forward-looking statements, and we refer you to our filings with the SEC regarding the risk factors that face our business.
So at Nurix, we are focused on targeted protein modulation, a new approach to making small molecule agents that can do one of two things -- either harness any E3 ligase as pictured here in the center of the screen -- harness it in order
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |